4 min read

Life-cycle management of a Swiss marketing authorisation: variations explained

Getting a medicine approved is only the beginning. Over its life on the market, almost everything about a product can change: the manufacturing site, a supplier, the packaging, the shelf life, the indications, and the safety information.
Variations are not only about manufacturing. Many of the most important ones are triggered by pharmacovigilance.

Getting a medicine approved is only the beginning. Over its life on the market, almost everything about a product can change: the manufacturing site, a supplier, the packaging, the shelf life, the indications, and the safety information. Each change must be assessed and, where required, approved by the authority before it reaches patients.

This process is called life-cycle management, and in Switzerland it is overseen by Swissmedic (Therapeutic Products Act [TPA], 2000). I studied it as part of the Regulatory Aspects for Approval of Therapeutics module of my MSc at the University of Basel. This article explains the main types of variations and how they are handled.

Why variations matter

A marketing authorisation describes one specific product, made in one specific way, with one specific set of information. If any of that changes without control, the authority's original assessment no longer applies.

Variations keep the authorisation accurate. They ensure that the product on the shelf is the product that was assessed, and that the product information reflects current knowledge.

The main categories

Swiss variation categories are largely aligned with the European system (Commission Regulation (EC) No 1234/2008, 2008; Ordinance on the Requirements for Authorisation [AMZV], 2001), which makes the logic familiar to regulatory professionals working across both markets.

TypeRisk levelTypical examplesGeneral procedure
IAMinimal impactAdministrative changes, minor quality changesNotification after implementation
IA(IN)Minimal impact, needs immediate noticeChange of a manufacturer's name or addressImmediate notification
IBMinor, not minimalSome changes to specifications or shelf lifeNotification before implementation; proceed if no objection
IIMajorNew indication, significant manufacturing change, major safety updateAssessment and approval before implementation

In addition, extensions, such as a new strength or pharmaceutical form, may require a new application rather than a variation (European Commission, 2013).

Swissmedic publishes guidance on the classification and documentation required for each type (Swissmedic, n.d.). Correct classification is the first critical decision, because under-classifying a change can lead to non-compliance.

Variations are not only about manufacturing. Many of the most important ones are triggered by pharmacovigilance.

When a safety signal is confirmed, the company may need to update the Swiss professional information (Fachinformation) and patient information (Patienteninformation). Updates can add a new adverse reaction, a warning, an interaction or a contraindication (Medicinal Products Ordinance [VAM], 2018).

Safety updates often require coordination across functions. Pharmacovigilance provides the evidence, regulatory affairs prepares and submits the variation, and medical and commercial teams prepare for the communication. Product information must be correct in German, French and Italian.

Assessing a change: the questions that matter

Before a variation is submitted, a regulatory team typically works through these questions:

  1. What exactly is changing? A precise description prevents misclassification.
  2. Which category applies? The classification guidance determines the procedure.
  3. What documentation is required? Updated sections of the dossier, supporting data and revised product information.
  4. Does the change affect other markets? Global companies coordinate timelines across countries.
  5. When can it be implemented? Some changes may be implemented only after approval.
  6. Is change control in place? Internally, quality assurance tracks the change from proposal to implementation (International Council for Harmonisation [ICH], 2008).

The last point links regulatory affairs to quality assurance. A manufacturing change, for example, goes through internal change control and must be reflected in both the quality system and the authorisation dossier.

Documentation and the dossier

Regulatory submissions follow the Common Technical Document structure, increasingly in electronic format (eCTD; ICH, 2016). Each variation updates the relevant modules, so the dossier remains a complete, current record of the product.

Accurate, consistent documentation is what allows an authority to assess a change efficiently. Errors or inconsistencies lead to questions, delays and, in some cases, rejection.

The pharmacist's view of a label change

As a pharmacist, I see the end result of this process. When a product information update introduces a new warning or interaction, it changes how I counsel patients and what I check at dispensing.

That perspective is useful on the regulatory side. It shows how product information is actually read and used, and why clear, consistent wording matters for patient safety.

Why this matters to employers

Life-cycle management is a large part of regulatory work for established portfolios. It requires precision, a good understanding of Swiss and international requirements, and close collaboration with quality, safety, medical and supply colleagues.

My regulatory training, my experience applying Swiss medicines law in practice and my attention to documentation detail prepare me to contribute to this work.

Key takeaways

  • Variations keep a marketing authorisation aligned with the actual product and current knowledge.
  • Swiss categories (IA, IA(IN), IB, II) are largely aligned with the EU system.
  • Safety updates link pharmacovigilance, regulatory affairs and the information pharmacists use daily.

References

Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products. (2008). Official Journal of the European Union, L 334, 7–24.

European Commission. (2013). Guidelines on the details of the various categories of variations, on the operation of the procedures laid down in Chapters II, IIa, III and IV of Commission Regulation (EC) No 1234/2008 (2013/C 223/01). Official Journal of the European Union, C 223, 1–79.

International Council for Harmonisation. (2008). Pharmaceutical quality system Q10. https://www.ich.org

International Council for Harmonisation. (2016). Organisation of the common technical document for the registration of pharmaceuticals for human use M4(R4). https://www.ich.org

Medicinal Products Ordinance [VAM] of 21 September 2018, SR 812.212.21 (Switzerland). https://www.fedlex.admin.ch

Ordinance on the Requirements for Authorisation [AMZV] of 9 November 2001, SR 812.212.22 (Switzerland). https://www.fedlex.admin.ch

Swissmedic. (n.d.). [Guidance on variations and extensions for authorised human medicinal products]. https://www.swissmedic.ch

Therapeutic Products Act [TPA] of 15 December 2000, SR 812.21 (Switzerland). https://www.fedlex.admin.ch